Day: January 12, 2023

Oramed Announces Top-line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes

NEW YORK , Jan. 11, 2023 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced today top-line results from its Phase 3 randomized, double-blind, placebo-controlled, multicenter

  • +1-844-9-ORAMED
  • office@oramed.com
  • 1185 Avenue of the Americas, New York, NY 10036 USA
Linkedin-in Facebook-f Twitter Youtube

Copyright © 2022 Oramed. | Terms & Conditions | Privacy Statement | Cookie Policy

Join our mailing list

  • +1-844-9-ORAMED
  • office@oramed.com
Linkedin-in Facebook-f Twitter Youtube
Home
About
Technology
Pipeline
Video Library
Contact us
NEWS
Press Releases
In the News
Scientific Articles and Abstracts
Events & Presentations
INVESTORS
Corporate presentation
Investor Relations
SEC filings
Investor FAQ
Governance documents
Investor tools
Oravax Medical
Skip to content
Open toolbar Accessibility Tools

Accessibility Tools

  • Increase TextIncrease Text
  • Decrease TextDecrease Text
  • GrayscaleGrayscale
  • High ContrastHigh Contrast
  • Negative ContrastNegative Contrast
  • Light BackgroundLight Background
  • Links UnderlineLinks Underline
  • Readable FontReadable Font
  • Reset Reset